Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc.SHPH · Entity 8505 | Director | December 29, 2022 | March 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shuttle Pharmaceuticals Holdings, Inc.
Report date December 29, 2022 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 2,791 |
Reported balance
After 2022-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-29 · Sale · Disposed 1,626 · Balance 2,791 F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,417 restricted stock units ("RSUs") held by the Reporting Person. Upon vesting of the RSUs, the sales are automatic, routine, non-discretionary transactions mandated by the Issuer under its equity incentive plan in order to satisfy the Reporting Person's tax withholding obligations which are funded by "sell to cover" transactions. These transactions are exempt under Section 16b-3 and do not represent discretionary trades by the Reporting Person. F2: Consists of 2,791 shares of SHPH common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,417 restricted stock units ("RSUs") held by the Reporting Person. Upon vesting of the RSUs, the sales are automatic, routine, non-discretionary transactions mandated by the Issuer under its equity incentive plan in order to satisfy the Reporting Person's tax withholding obligations which are funded by "sell to cover" transactions. These transactions are exempt under Section 16b-3 and do not represent discretionary trades by the Reporting Person.
F2: Consists of 2,791 shares of SHPH common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2022 Filed Mar 14, 2024 21:02 UTC | Shuttle Pharmaceuticals Holdings, Inc. SHPH · Entity 8505 | SaleCOMMON STOCK | 1,626 | $1.61 | $2,609.73 |
DisclosureSEC source: 0001493152-24-009980 · ownership.xml · nonDerivative · entry 1 Senanayake Chris · CIK 0001945766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,791 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,417 restricted stock units ("RSUs") held by the Reporting Person. Upon vesting of the RSUs, the sales are automatic, routine, non-discretionary transactions mandated by the Issuer under its equity incentive plan in order to satisfy the Reporting Person's tax withholding obligations which are funded by "sell to cover" transactions. These transactions are exempt under Section 16b-3 and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Consists of 2,791 shares of SHPH common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.